Lepretre, Stephane <br/><br/>
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.  [electronic resource] 

 -  Blood  May 2012 
 - 5104-10 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2011-07-365437  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Rituximab<br/>Survival Rate<br/>Time Factors<br/>Vidarabine--administration & dosage